Brenda Olmos
Family · Austin, TXNPI 1811410392
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 91.9% of the total across 124 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 41 manufacturers, the largest accounting for just 18.7% — the pattern of someone who eats at a lot of different presentations. Among family clinicians in TX with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 124 payments — averaging $97.98 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$2K
- Corcept Therapeutics$1K
- Sanofi$893
- Gilead$697
- Inspire Medical Systems, Inc.$644
- Abbott$588
- plus $6K from 35 others
What the payments were for
- Speaking & faculty fees$9638%
- Travel & lodging$180%
- Food & beverage$11,16992%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 24 | $2,274 |
| Corcept Therapeutics | 11 | $1,439 |
| Sanofi | 8 | $893 |
| Gilead | 6 | $697 |
| Inspire Medical Systems, Inc. | 5 | $644 |
| Abbott | 9 | $588 |
| GSK | 5 | $568 |
| Amgen(2 entities) | 5 | $555 |
| Genentech USA, Inc. | 3 | $362 |
| Genentech, Inc. | 4 | $349 |
| Teva Pharmaceuticals USA, Inc. | 4 | $334 |
| Takeda Pharmaceuticals U.S.A., Inc. | 3 | $302 |
| AbbVie | 4 | $292 |
| Phathom Pharmaceuticals, Inc. | 2 | $230 |
| Biohaven Pharmaceutical Holding Company Ltd. | 2 | $217 |
| Johnson & Johnson(2 entities) | 2 | $192 |
| Pfizer | 2 | $154 |
| Otsuka America Pharmaceutical, Inc. | 1 | $125 |
| Boston Scientific | 1 | $124 |
| Neurocrine Biosciences, Inc. | 1 | $123 |
| Viiv Healthcare Company | 1 | $122 |
| Stemline Therapeutics Inc. | 1 | $122 |
| Theratechnologies Inc. | 1 | $119 |
| Scynexis, Inc. | 1 | $116 |
| Kyowa Kirin, Inc. | 1 | $115 |
| Acadia Pharmaceuticals Inc | 1 | $115 |
| Sandoz | 1 | $112 |
| Penumbra, Inc. | 1 | $112 |
| Amarin Pharma, Inc. | 1 | $103 |
| Astellas Pharma US Inc | 1 | $97 |
| Bridgebio Pharma, Inc. | 1 | $94 |
| Shield Therapeutics Inc | 1 | $91 |
| Ultragenyx Pharmaceutical Inc. | 1 | $88 |
| Teleflex LLC | 1 | $84 |
| Shockwave Medical, Inc | 2 | $49 |
| Sanofi-aventis U.S. LLC | 1 | $38 |
| Organon | 1 | $25 |
| Irhythm Technologies, Inc. | 1 | $24 |
| Dexcom, Inc. | 1 | $22 |
| Exact Sciences | 1 | $20 |
| Medtronic | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Korlym$1,316
- Inspire$519
- Repatha$375
- OCREVUS$275
- Descovy$249
- VOQUEZNA$230
- FREESTYLE LIBRE 3$225
- VRAYLAR$133
- Xofluza$126
- Inspire Upper Airway Stimulation System$125
- UBRELVY$125
- BENLYSTA$125
- REXULTI$125
- WATCHMAN FLX$124
- Epclusa$123
- INGREZZA$123
- APRETUDE$122
- ELZONRIS$122
- AIRSUPRA$122
- NURTEC ODT$121
How this compares
$12,149 in reported general payments places this provider in the 95th percentile of 15,456 family providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Atorvastatin Calcium | 25 | $345 |
| Metformin Hcl | 11 | $112 |
| Levothyroxine Sodium | 12 | $76 |
| Losartan Potassium | 11 | $71 |
| Lisinopril | 12 | $21 |
Paid to pharmacies, not to this prescriber.
Other family in Austin
- Monique MulvanyAustin$142K
- Barry HughesAustin$51K
- Eric PerezAustin$42K
- Chelsea CrillyAustin$36K
- Alexandra RossiAustin$35K
- Angelina DetmersAustin$33K
- David WeirDallas$959K
- Robin BeachHouston$428K
- April LopezMcAllen$417K
- Sarah AguilarHouston$199K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.